Research site

Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p.

Poland Ul. Partyzantow 30a, 35-234 Rzeszow, Poland

Hormone receptor positive breast cancer · HER2 positive breast cancer
Adult patients

About Specializations

Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p. in Rzeszow, Poland specialises in clinical trials of conditions such as Hormone receptor positive breast cancer, HER2 positive breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on breast cancer. The institution is dedicated to advancing treatment options for patients with locally advanced or metastatic breast cancer, especially those with HER2 and oestrogen receptor positivity.

Breast Cancer
HER2-Positive Cancer
Hormone Receptor-Positive Cancer

Through innovative clinical trials, the center is evaluating the efficacy of novel therapeutic combinations, such as giredestrant with Phesgo, to improve progression-free survival in patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Partyzantow 30a35-234 RzeszowPoland

Open in maps ↗

Recruiting now: no trials
Conditions studied: 2

More sites in Rzeszow Poland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

1 clinical trial

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites